Group B adenovirus encoding an anti-TCR-complex antibody or fragment

Inventors

CHAMPION, BRIAN ROBERT • BROWN, Alice Claire Noel

Assignees

Akamis Bio Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11970536-B2

Patent

Publication Date

2024-04-30

Expiration Date


Abstract

The present disclosure relates to a replication deficient oncolytic viral vector or replication capable group B oncolytic adenovirus selected from the group consisting of Ad11 and enadenotucirev, wherein the virus encodes an antibody or a binding fragment thereof for expression on the surface of a cancer cell, wherein said antibody or binding fragment is specific to a CD3 protein of a T-cell receptor complex (TCR), wherein the virus does not encode a B7 protein or an active fragment thereof, pharmaceutical compositions comprising the same, and use of any one of the same in treatment, particularly in the treatment of cancer.

Core Innovation

The invention relates to replication capable group B oncolytic adenoviruses selected from Ad11 and enadenotucirev (EnAd). The adenovirus comprises a transgene encoding an antibody or a binding fragment thereof for expression on the surface of a cancer cell, and the antibody or binding fragment is specific to a CD3 protein of a T-cell receptor complex (TCR).

The gene encoding the antibody or binding fragment is located between the adenoviral gene L5 and the gene E4, and the transgene is under the control of the endogenous major late promoter of the adenovirus. The encoded antibody further comprises a transmembrane domain or a GPI anchor, and the adenovirus encodes at least one further transgene.

The further transgene or transgenes encode proteins independently selected from cytokines, chemokines, antagonistic antibody molecules or binding fragments, agonistic antibody molecules or binding fragments, and combinations thereof. The one or more further transgenes are between the gene E4 and the gene L5 under the control of the major late promoter of the adenovirus, and the adenovirus does not encode a B7 protein or an active fragment thereof.

Claims Coverage

The consolidated claims content includes one independent claim covering a replication capable group B oncolytic adenovirus selected from Ad11 and EnAd, with at least four inventive features integrated in the claim set.

Replication capable group B oncolytic adenovirus selected from Ad11 and EnAd

A replication capable group B oncolytic adenovirus selected from Ad11 and enadenotucirev (EnAd).

Anti-CD3 surface expression transgene between L5 and E4

A transgene encodes an antibody or binding fragment specific to a CD3 protein of a T-cell receptor complex (TCR), and the gene encoding the antibody or binding fragment is located between the adenoviral gene L5 and the gene E4.

Endogenous major late promoter control and antibody anchoring

The transgene encoding the anti-CD3 antibody or binding fragment is under the control of the endogenous major late promoter of the adenovirus, and the encoded antibody comprises a transmembrane domain or a GPI anchor.

Further transgenes between E4 and L5 under major late promoter and B7 exclusion

The adenovirus encodes at least one further transgene between the gene E4 and the gene L5 under the control of the major late promoter, wherein the further transgene encodes a cytokine, a chemokine, an antagonistic antibody molecule or binding fragment, an agonistic antibody molecule or binding fragment, or combinations thereof, and the adenovirus does not encode a B7 protein or an active fragment thereof.

The claims center on a replication capable group B oncolytic adenovirus carrying an anti-CD3 transgene positioned between L5 and E4 and controlled by the endogenous major late promoter, with transmembrane domain or GPI anchoring for cancer cell surface expression. The claim set also includes additional transgenes between E4 and L5 under the same promoter and excludes B7 protein or active fragments.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Not explicitly described in patent.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.